Catalyst Pharmaceuticals (NASDAQ:CPRX) Given Outperform Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the company. Citigroup began coverage on Catalyst […]

Related Keywords

United States ,America ,Brian Elsbernd ,Parkside Financial Bank ,News Ratings For Catalyst Pharmaceuticals Daily ,Covestor Ltd ,Catalyst Pharmaceuticals ,Securities Exchange Commission ,Catalyst Pharmaceuticals Stock Performance ,Catalyst Pharmaceuticals Inc ,Citigroup ,Cantor Fitzgerald ,Analyst Recommendations For Catalyst Pharmaceuticals ,Advisory Services Network ,Visionpoint Advisory Group ,Free Report ,Get Free Report ,Exchange Commission ,Services Network ,Financial Bank ,Catalyst Pharmaceuticals Daily ,